IMPL - Impel stock rises as dosing begins in mid-stage trial of INP105 for agitation in autistic people
- Impel Pharmaceuticals ( NASDAQ: IMPL ) stock rose ~4% on July 19 after the company said that the first person was dosed in a phase 2a trial of nasal-delivered antipsychotic olanzapine, INP105, for the acute treatment of agitation in people with autism spectrum disorder (ASD).
- The company noted that it is developing INP105 using its proprietary Precision Olfactory Delivery technology which delivers drugs to the upper nasal space.
- The study will enroll patients 12 to ? 18 years of age with ASD experiencing agitation, who will either receive INP105 or placebo.
- The main goals of the trial are to evaluate the incidences of adverse events (AEs) and serious AEs in both groups at 48 hours post-dose and overall. Meanwhile, secondary goals are to evaluate the efficacy over two hours with a single dose of INP105 versus placebo on acute agitation in the patients.
- The company expects results in Q1 2023.
For further details see:
Impel stock rises as dosing begins in mid-stage trial of INP105 for agitation in autistic people